Skip to main content

Advertisement

SpringerLink
Log in

Permanent seed implantation for localized adenocarcinoma of the prostate

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Prostate brachytherapy has become a popular treatment option for localized prostate cancer with over 44,000 procedures performed in 2000. Eighty-seven percent to 93% of patients who have a serum prostate-specific antigen less than 10 ng/mL, Gleason score of 6 or less, and low risk (disease stage ≤ T2a) can be expected to have an 8 to 10 year disease-free rate. The radiation dose delivered by the implants should exceed 140 Gy in men implanted with I-125 monotherapy. Patients with intermediate- and highrisk prostate cancer would benefit from the addition of either hormonal therapy and/or external beam irradiation to the implantation of seeds. Postimplant incontinence and proctitis can be minimized by controlling high radiation doses to the urethra and rectum. Potency is preserved in 70% of men with good preimplantation erectile function. Advances in technology, such as intraoperative dosimetry, will continue to make brachytherapy an attractive treatment option for men with localized prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pasteau O, Degrais P: The radium treatment of cancer of the prostate. J D’Urol (Paris) 1913, 4:341–366.

    Google Scholar 

  2. Flocks RH, Kerr HD, Elkins H, et al.: Treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au 198): a preliminary report. J Urol 1952, 68:516–522.

    Google Scholar 

  3. Whitmore WF, Hilaris B, Grabstald H: Retropubic implantation of Iodine 125 in the treatment of prostate cancer. J Urol 1972, 108:918–920.

    PubMed  Google Scholar 

  4. Holm HH, Pedersen JF, Hansen H, Stroyer I: Transperineal I-125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983, 30:283–286.

    Google Scholar 

  5. Blasko JC, Radge H, Schumacher D: Transperineal percutaneous Iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurie Hypertherm Oncol 1987, 3:131–139.

    Google Scholar 

  6. Jemal A, Thomas A, Murray T, Thun M: Cancer Statistics, 2002. CA Cancer J Clin 2002, 52:23–47.

    Article  PubMed  Google Scholar 

  7. Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1991, 23:81–87.

    Google Scholar 

  8. Anderson LL, Moni JV, Harrison LB: A nomogram for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys 1993, 27:129–135.

    CAS  PubMed  Google Scholar 

  9. Nath R, Meigooni AS, Melillo A: Some treatment planning considerations for Pd-103 and I-125 permanent interstitial implants. Int J Radiat Oncol Biol Phys 1992, 22:1131–1138.

    Article  CAS  PubMed  Google Scholar 

  10. Fontenla DP, Ahmad M, Chiu-Tsao S, Anderson LL: Diode dosimetry of Pd-103 model 200 seed in water phantom. Med Phys 1994, 21:817–826.

    Article  CAS  PubMed  Google Scholar 

  11. Meigooni AS, Sabanis S, Nath R: Dosimetry of palladium-103 brachytherapy sources for permanent implants. Endocurie Hypertherm Oncol 1990, 6:107–117.

    Google Scholar 

  12. Chiu-Tsao S, Anderson LL: Thermoluminescent dosimetry for PD-103 (model 200) in solid water phantom. Med Phys 1991, 18:449–452.

    Article  CAS  PubMed  Google Scholar 

  13. Blasko JC, Radge H, Schumacher D: Transperineal percutaneous Iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurie Hypertherm Oncol 1987, 3:131–139.

    Google Scholar 

  14. Ragde H, Blasko JC, Grimm PD, et al.: Interstitial Iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997, 80:442–453.

    Article  CAS  PubMed  Google Scholar 

  15. Stock RG, Stone NN, Wesson MF, DeWyngaert JK: A modified technique allowing interactive ultrasound-guided threedimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995, 32:219–225.

    CAS  PubMed  Google Scholar 

  16. Stone NN, Ramin SA, Wesson MF, et al.: Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995, 153:1555–1560.

    Article  CAS  PubMed  Google Scholar 

  17. Stone NN, Stock RG, DeWyngaert JK, Tabert A: Prostate brachytherapy: improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiat Oncol Investig 1995, 3:185–195.

    Article  Google Scholar 

  18. Paterson R, Parker HM: A dosage system for gamma-ray therapy, Parts 1 and 2. Br J Radiol 1943, 7:592–632.

    Article  Google Scholar 

  19. Tapen EM, Blasko JC, Grimm PD, et al.: Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 42:1063–1067.

    Article  CAS  PubMed  Google Scholar 

  20. Stone NN, Stock RG, Hong S: Pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Eur J Cancer 2001, 37:574a.

    Article  Google Scholar 

  21. Nag S, Bice W, DeWyngaert K, et al.: The American Brachytherapy Society recommendations for permanent prostate brachytherapy post-implant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000, 46:221–230. This article reviews the published data on prostate implant dosimetry. The authors include recommendations for CT-based postimplant dosimetry and which quality parameters should be recorded.

    Article  CAS  PubMed  Google Scholar 

  22. Stone NN, Stock RG: 8 year treatment results of prostate brachytherapy. J Urol 2002, 167:1560a.

    Article  Google Scholar 

  23. Dattoli MJ, Wallner KE, Cash JC, et al.: Palladium-103 brachytherapy for clinical T1/T2 prostate carcinomas. Int J Radiat Oncol Biol Phys 1997, 39:220.

    Google Scholar 

  24. Ragde H, Abdel-Aziz AE, Snow PB, et al.: Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998, 83:989–1001.

    Article  CAS  PubMed  Google Scholar 

  25. Grimm PD, Blasko JC, Sylvester JE, et al.: 10 year biochemical (prostate specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Rad Oncol Biol Phys 2001, 49:31–40. Describes the 10-year outcomes of I-125 prostate brachytherapy. Patients treated prior to January 1, 1988 had inferior outcomes compared with more recently treated patients.

    Google Scholar 

  26. Lederman GS, Cavanagh W, Albert PS, et al.: Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external beam radiotherapy and brachytherapy. Int J Rad Oncol Biol Phys 2001, 49:1297–1303. Describes improved outcomes for patients with high-risk prostate cancer treated by a combination of seed implantation and EBRT.

    Article  CAS  Google Scholar 

  27. Stock RG, Stone NN, Tabert A, et al.: A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998, 41:101–108. First publication to set the dosimetry standard for I-125 implants. Patients must receive a dose of 140 Gy following seed implantation.

    Article  CAS  PubMed  Google Scholar 

  28. Critz FA, Tarlton RS, Holladay DA: Prostate specific antigenmonitored combination radiotherapy for patients with prostate cancer: I-125 implant followed by external-beam radiation. Cancer 1995, 75:2383–2391.

    Article  CAS  PubMed  Google Scholar 

  29. Dattoli M, Wallner K, Sorace R, et al.: 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996, 35:1–5.

    Article  Google Scholar 

  30. Lee LN, Stock RG, Stone NN: The role of hormone therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Rad Oncol Biol Phys 2002, 52:444–452. Hormonal therapy improves the success rate of brachytherapy in moderate- and high-risk patients.

    Article  CAS  Google Scholar 

  31. Stock RG, Stone NN, Hong S: Is long term hormonal therapy needed with dose escalation in high risk prostate cancer? Results of treatment with 9 months of hormonal therapy, brachytherapy and 3D conformal external beam irradiation. Int J Rad Oncol Biol Phys 2001, 51:2127a.

    Google Scholar 

  32. Blasko JC, Wallner K, Grimm PD, Ragde H: Prostate specific antigen based disease control following ultrasound guided 125Iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995, 154:1096–1099.

    Article  CAS  PubMed  Google Scholar 

  33. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996, 14:449–453.

    CAS  PubMed  Google Scholar 

  34. Zeitlin SI, Sherman J, Raboy A, et al.: High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998, 160:91–96.

    Article  CAS  PubMed  Google Scholar 

  35. Terk MD, Stock RG, Stone NN: Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160:1379–1382.

    Article  CAS  PubMed  Google Scholar 

  36. Vijverberg PLM, Blank LECM, Dabhoiwala NF, et al.: Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. Br J Urol 1993, 72:470–477.

    Article  CAS  PubMed  Google Scholar 

  37. Kaye KW, Olson DJ, Payne JT: Detailed preliminary analysis of 125Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995, 153:1020–1025.

    Article  CAS  PubMed  Google Scholar 

  38. Kleinberg L, Wallner K, Roy J, et al.: Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994, 28:985–990.

    Article  CAS  PubMed  Google Scholar 

  39. Desai J, Stock RG, Stone NN, et al.: Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998, 6:135–141.

    Article  CAS  PubMed  Google Scholar 

  40. Stone NN, Ratnow ER, Stock RG: Prior transurethral resection does not increase morbidity following real-time ultrasound guided prostate seed implantation. Tech Urol 2000, 6:123–127.

    CAS  PubMed  Google Scholar 

  41. Snyder KM, Stock RG, Hong SM, et al.: Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Rad Oncol Biol Phys 2001, 50:335–341. Details how radiation proctitis can be caused by overirradiation of the rectum. Makes recommendations about safe rectal doses following I-125 brachytherapy.

    Article  CAS  Google Scholar 

  42. Stone NN, Stock RG: Prostate brachytherapy: treatment strategies. J Urol 1999, 162:421–426.

    Article  CAS  PubMed  Google Scholar 

  43. Stock RG, Kao J, Stone NN: Penile erection function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001, 165:436–439.

    Article  CAS  PubMed  Google Scholar 

  44. Nag S, Ciezki JP, Cormack R, et al.: Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Rad Oncol Biol Phys, 2001:1422–1430.

  45. Stock RG, Stone NN, Lo YC: Intraoperative dosimetric representation of the real-time ultrasound guided prostate implant. Tech Urol 2000, 6:95–98.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology and Radiation Oncology, Mount Sinai School of Medicine, One Gustave Levy Place, 10029, New York, NY, USA

    Nelson N. Stone MD & Richard G. Stock MD

Authors
  1. Nelson N. Stone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard G. Stock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stone, N.N., Stock, R.G. Permanent seed implantation for localized adenocarcinoma of the prostate. Curr Urol Rep 3, 201–206 (2002). https://doi.org/10.1007/s11934-002-0065-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-002-0065-9

Keywords

Search

Navigation